Monoclonal antibody which specifically binds to cd20
RU2739489C2
Novel heterocyclic compounds as cdk8/19 inhibitors
RU2665790C1
Monoclonal pd-l1 antibody
RU2641001C1
Salts of 4-((2-(6-(4-methylpiperazine-1-carbonyl)-naphthalen-2-yl)ethyl) amino)quinazoline-6-carbonitrile and pharmaceutical composition
RU2665966C2
Recombinant monoclonal antibody to tnf-alpha aqueous pharmaceutical composition
RU2656160C2
Antibody or its anti-binding fragment, which is capable to be bound using the interleukin-6 human receptor
RU2653443C2
Bispecific anti-her2 / anti-her3 antibodies
RU2656181C1
Anti-pd-1 antibodies, method for their production, and method of application
RU2680011C2
Trispecific il-17a, il-17f and other proinflammatory molecules antibodies
RU2647769C2
Chemeric improved recombinant factor viii
RU2664588C2
Extended factor of human erythropoiesis and a therapeutic agent based thereon
RU2639424C2
Solid oral pharmaceutical composition of s1p agonist or its pharmaceutically acceptable salt, method for its production and methods for treatment and reduction of frequency of clinical exacerbations of multiple sclerosis
RU2609627C2
High affinity and aggregationally stable antibodies based on vl variable domains and vhh derivative
